Literature DB >> 24830864

Enhanced diacylglycerol production by phospholipase D activation is responsible for abnormal increase in concanavalin A cap formation in polymorphonuclear leukocytes from Chediak-Higashi syndrome (beige) mice.

Hirotake Kasai1, Fuminori Tanabe2.   

Abstract

We previously reported that enhanced ceramide production induces calpain-mediated proteolysis of protein kinase C (PKC) in leukocytes from Chediak-Higashi syndrome (CHS). In the present study, we demonstrated that phospholipase D (PLD) inhibitors ameliorated abnormal increases in concanavalin A (Con A) cap formation in polymorphonuclear leukocytes (PMNs) from beige mouse, an animal model of CHS. PLD activity in PMNs from beige mice enhanced at 30 to 60s after Con A stimulation. In Con A-stimulated beige PMNs, both neutral sphingomyelinase (N-SMase) and acidic sphingomyelinase (A-SMase) activities enhanced, and ceramide levels are also increased. We found that ceramide levels were reversed by the treatment of beige PMNs with propranolol which inhibits phosphatidic acid phosphohydrolase. In addition, we showed that diacylgycerol (DAG) analogs enhance both N-SMase and A-SMase activities in PMNs from normal mice. We subsequently examined the association of CHS1 with PLD, and showed that expression of a truncated mutant of CHS1 in 293T cells induced abnormally rapid activation of PLD after phorbol ester stimulation. Moreover, we showed that specific inhibitors of 14-3-3 proteins, which interact with CHS1/LYST and bind PKC, did not affect abnormal increases in Con A cap formation in beige PMNs. These results suggest that the enhanced DAG production via the PLD pathway is associated with abnormal increases in Con A cap formation in beige PMNs, and that CHS1 may be involved in the regulation of PLD activity.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CHS1/LYST; Calpain; Ceramide; Chediak–Higashi syndrome; Phospholipase D; Protein kinase C

Mesh:

Substances:

Year:  2014        PMID: 24830864     DOI: 10.1016/j.intimp.2014.05.003

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  1 in total

Review 1.  Towards the targeted management of Chediak-Higashi syndrome.

Authors:  Maria L Lozano; Jose Rivera; Isabel Sánchez-Guiu; Vicente Vicente
Journal:  Orphanet J Rare Dis       Date:  2014-08-18       Impact factor: 4.123

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.